These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35073398)

  • 1. Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes.
    Liu YF; Powrie J; Arif S; Yang JHM; Williams E; Khatri L; Joshi M; Lhuillier L; Fountoulakis N; Smith E; Beam C; Lorenc A; Peakman M; Tree T
    Diabetes; 2022 Apr; 71(4):722-732. PubMed ID: 35073398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.
    Alhadj Ali M; Liu YF; Arif S; Tatovic D; Shariff H; Gibson VB; Yusuf N; Baptista R; Eichmann M; Petrov N; Heck S; Yang JHM; Tree TIM; Pujol-Autonell I; Yeo L; Baumard L; Stenson R; Howell A; Clark A; Boult Z; Powrie J; Adams L; Wong FS; Luzio S; Dunseath G; Green K; O'Keefe A; Bayly G; Thorogood N; Andrews R; Leech N; Joseph F; Nair S; Seal S; Cheung H; Beam C; Hills R; Peakman M; Dayan CM
    Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes.
    Bergot AS; Buckle I; Cikaluru S; Naranjo JL; Wright CM; Zheng G; Talekar M; Hamilton-Williams EE; Thomas R
    J Immunol; 2020 Apr; 204(7):1787-1797. PubMed ID: 32111734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.
    Gibson VB; Nikolic T; Pearce VQ; Demengeot J; Roep BO; Peakman M
    Clin Exp Immunol; 2015 Dec; 182(3):251-60. PubMed ID: 26206289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
    Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
    Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
    Thrower SL; James L; Hall W; Green KM; Arif S; Allen JS; Van-Krinks C; Lozanoska-Ochser B; Marquesini L; Brown S; Wong FS; Dayan CM; Peakman M
    Clin Exp Immunol; 2009 Feb; 155(2):156-65. PubMed ID: 19040615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens.
    Durinovic-Belló I
    Autoimmunity; 1998; 27(3):159-77. PubMed ID: 9609134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1β produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: Implications for the timing of tolerizing immunotherapy.
    Bertin-Maghit S; Pang D; O'Sullivan B; Best S; Duggan E; Paul S; Thomas H; Kay TW; Harrison LC; Steptoe R; Thomas R
    Diabetes; 2011 Jan; 60(1):248-57. PubMed ID: 20980463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Bioconjugate Platform for Modifying the Immune Response of Autoreactive Cytotoxic T Lymphocytes Involved in Type 1 Diabetes.
    Nandedkar-Kulkarni N; Vartak AR; Sucheck SJ; Wall KA; Quinn A; Morran MP; McInerney MF
    Bioconjug Chem; 2019 Jul; 30(7):2049-2059. PubMed ID: 31274300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8
    Xu X; Bian L; Shen M; Li X; Zhu J; Chen S; Xiao L; Zhang Q; Chen H; Xu K; Yang T
    Diabetologia; 2017 Dec; 60(12):2418-2431. PubMed ID: 28887632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes.
    Pujol-Autonell I; Serracant-Prat A; Cano-Sarabia M; Ampudia RM; Rodriguez-Fernandez S; Sanchez A; Izquierdo C; Stratmann T; Puig-Domingo M; Maspoch D; Verdaguer J; Vives-Pi M
    PLoS One; 2015; 10(6):e0127057. PubMed ID: 26039878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
    Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Perry DJ; Schultz AR; Hulme MA; Shuster JJ; Zou B; Wasserfall CH; Posgai AL; Mathews CE; Brusko TM; Atkinson MA; Schatz DA
    Diabetes; 2016 Dec; 65(12):3765-3775. PubMed ID: 27669730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet autoimmunity.
    Boitard C
    Presse Med; 2012 Dec; 41(12 P 2):e636-50. PubMed ID: 23182678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes.
    Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA
    Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways.
    Wang J; Lu J; Lan Y; Zhou H; Li W; Xiang M
    J Ethnopharmacol; 2013 Mar; 146(1):379-92. PubMed ID: 23340441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
    Fändrich F; Ungefroren H
    Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
    Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
    Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes.
    Houeiss P; Boitard C; Luce S
    Front Endocrinol (Lausanne); 2022; 13():883000. PubMed ID: 35498419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes.
    Azam A; Eisenbarth GS
    Expert Opin Biol Ther; 2004 Oct; 4(10):1569-75. PubMed ID: 15461568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of New Onset Type 1 Diabetes by Oral
    Mbongue JC; Rawson J; Garcia PA; Gonzalez N; Cobb J; Kandeel F; Ferreri K; Husseiny MI
    Front Immunol; 2019; 10():320. PubMed ID: 30863412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.